Impact of key manifestations of psoriatic arthritis on patient quality of life, functional status, and work productivity: Findings from a real-world study in the United States and Europe-Reference-Cited by-同舟云学术

Impact of key manifestations of psoriatic arthritis on patient quality of life, functional status, and work productivity: Findings from a real-world study in the United States and Europe

Published:2023-05 Issue:3 Volume:90 Page:105534
ISSN:1297-319X
Container-title:Joint Bone Spine
language:en
Short-container-title:Joint Bone Spine

Author:

Walsh Jessica A.,Ogdie Alexis,Michaud Kaleb,Peterson Steven,Holdsworth Elizabeth A.,Karyekar Chetan S.,Booth Nicola,Middleton-Dalby Chloe,Chakravarty Soumya D.,Dennis Natalie,Gossec Laure

Funder

Janssen Pharmaceuticals Inc

Publisher

Elsevier BV

Subject

Rheumatology

Reference37 articles.

1. GRAPPA treatment recommendations: 2021 update;Coates;J Rheumatol,2022

2. Effect of multidomain disease presentations on patients with psoriatic arthritis in the Corrona psoriatic arthritis/spondyloarthritis registry;Ogdie;J Rheumatol,2021

3. Epidemiology of psoriatic arthritis in the population of the United States;Gelfand;J Am Acad Dermatol,2005

4. Interval between onset of psoriasis and psoriatic arthritis comparing the UK Clinical Practice Research Datalink with a hospital-based cohort;Tillett;Rheumatology (Oxford),2017

5. Peripheral joint involvement in psoriatic arthritis patients;Acosta Felquer;Clin Exp Rheumatol,2015

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Health state utility values in patients with Ankylosing Spondylitis: a systematic review and meta-analysis;Quality of Life Research;2024-06-01

2. Effect of bimekizumab on patient-reported disease impact in patients with psoriatic arthritis: 1-year results from two phase 3 studies;Rheumatology;2024-05-16

3. Association between enthesitis/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritis;Clinical Rheumatology;2024-03-12

4. Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study;RMD Open;2024-03

5. Work Productivity and General Health Through 2 Years of Guselkumab Treatment in a Phase 3 Randomized Trial of Patients With Active Psoriatic Arthritis;Rheumatology and Therapy;2024-02-22